A major drawback of earlier BH3 mimetics targeting multiple Bcl-2 proteins, such as navitoclax, was their on-target/off-tumor inhibition of Bcl-xL in platelets, resulting in dose-limiting thrombocytopenia [38]. This evidence concerns the gene BCL2L1 and neoplasm.